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RIASSUNTO 
 
Introduzione 
Il trattamento standard del cancro rettale localmente avanzato è rappresentato 
dalla radiochemioterapia preoperatoria (pRCT) seguita dalla chirurgia. Tuttavia, la 
risposta alla pRCT non è uniforme e non esiste oggi un metodo efficace per predire la 
risposta tumorale alla pRCT. L'identificazione di pazienti non responsivi alla pRCT 
potrebbe evitare l'esposizione alla radio- e chemioterapia, trattamenti non scevri da 
affetti avversi; inoltre l'identificazioni delle risposte complete potrebbe selezionare 
pazienti candidati ad un trattamento chirurgico meno invasivo. Questo studio si propone 
di associare profili di espressione genica e di microRNA (miRNA) al grado di risposta 
tumorale in pazienti affetti da cancro rettale e sottoposti a pRCT. 
Materiali e metodi 
Pazienti consecutivi affetti da carcinoma rettale medio-basso localmente 
avanzato e candidati quindi a pRCT, sono stati sottoposti a biopsie tissutali multiple 
prima dell'inizio della pRCT. Tutti i pazienti sono stati quindi sottoposti a pRCT 
standard seguita dalla resezione chirurgica del tumore. Tutti i pezzi operatori sono stati 
analizzati da uno stesso team di patologi ed in modo standardizzato. Le biopsie con una 
percentuale di cellule tumorali ≥50% sono state considerate idonee per gli esperimenti. 
Previo isolamento del RNA, l'espressione genica e di miRNA è stata valutata con 
tecnica microarray one color (Agilent®). I dati ottenuti sono stati quindi normalizzati 
sia intra- che inter-array, filtrati e infine clusterizzati. L'espressione genica e di miRNA 
è stata comparata tra responders (R) e non responders (NR) in base al grado di 
regressione tumorale (TRG) valutato dal patologo al momento dell'esame del pezzo 
operatorio. Una validazione dei dati ottenuti con i microarray è stata fatta mediante  
PCR quantitativa (qPCR). 
Risultati 
Sono stati considerati per lo studio 38 pazienti, 16 (42%) R (TRG1-2) e 22 
(58%) NR (TRG3-5). Nonostante una prima unsupervised cluster analisi non abbia 
separato nettamente i due gruppi di pazienti, usando il programma SAM (Significance 
Analysis of Microarray) two class, 256 trascritti sono risultati differenzialmente espressi 
tra NR e R (188 sovra- e 68 sotto-espressi). Usando PAM (Prediction Analysis for 
Microarray), 12 trascritti erano fortemente predittivi di risposta tumorale. SAM two 
class ha permesso inoltre di evidenziare 30 miRNA differenzialmente espressi tra NR e 
R (24 sovra- e 6 sotto-espressi). Analisi di anti-correlazione, mediante MAGIA (miRNA 
and genes integrated analysis), hanno rilevato gli stessi 8 miRNA sia nel gruppo NR 
che R, ad eccezione di miR-630, sovra-espresso solo nei NR. La validazione mediante 
qPCR del gene ABCC2 e di miR-7, miR-182, miR-200a, miR-630, miR-638 e miR-
1300 ha confermato i risultati dell'analisi microarray. 
Conclusioni  
I profili di espressione genica e di miRNA pre-trattamento sembrano essere utili 
alla predizione di risposta tumorale alla pRCT in pazienti affetti da cancro del retto, 
tuttavia sono necessari ulteriori studi di validazione per confermare questi risultati e per 
il loro utilizzo nella pratica clinica. 
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SUMMARY 
 
Background 
Preoperative chemoradiotherapy (pCRT) followed by surgery is the standard 
treatment for locally advanced rectal cancer (LARC). However, the response to pCRT is 
not uniform, and there is no effective method to predict tumour response to pCRT. 
Identification of patients not responsive to pCRT could avoid useless exposure to 
radiation or chemotherapy which is associated with adverse effects. Moreover, the 
identification of pathological complete response could select patients candidated to a 
more preserving surgery. The aim of this study is to investigate whether gene and 
micro-RNA (miRNA) expression profiling is associated with rectal cancer response to 
pCRT. 
 
Materials and methods 
Tissue biopsies were obtained from patients with mid-low LARC, before pCRT. 
All the patients underwent standard pCRT followed by resection. All surgical 
specimens underwent standardized histopathological examination. The biopsies with 
≥50% of cancer tissue were considered for the experiment. Gene and miRNA 
expression was analyzed using one color microarrays technique (Agilent®), after RNA 
isolation. The data were normalized intra- and inter-array, filtered and then clustered. 
Gene and miRNA expression was compared between responders (R) and non 
responders (NR) as measured by histopathological tumour regression grade (TRG). 
Validation of microarrays data was made by quantitative PCR (qPCR). 
 
Results 
Thirty-eight patients, 16 (42%) R (TRG1-2) and 22 (58%) NR (TRG3-5), were 
considered. Using SAM (Significance Analysis of Microarrays) two class, 256 genes 
were found differentially expressed between NR and R (188 over- and 68 down-
expressed). Performing PAM (Prediction Analysis for Microarray), 12 genes were 
strongly predictive of tumour response. Using SAM two class, 30 miRNAs were found 
differentially expressed between NR and R (24 over- and 6 down-expressed). Anti-
correlation analyses, using MAGIA (miRNA and genes integrated analysis), revealed 
the same 8 miRNAs both in NR and R group, except for miR-630, over-expressed only 
in NR group. ABCC2 gene, miR-7, miR-182, miR-200a, miR-630, miR-638, and miR-
1300 were validated by qPCR, confirming the data obtained by microarray analysis. 
 
Conclusions 
Pre-treatment gene and miRNA expression profiling may be helpful to predict 
response to pCRT in LARC. Further analyses to confirm these findings are required. 
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BACKGROUND 
 
Colorectal cancer (CRC) is the third most common cancer diagnosis among both 
genders, with an estimated 663,600 new cases and 320,600 deaths per year worldwide1. 
Approximately 20% of CRCs are distal to the rectosigmoid junction and designated as 
rectal cancer. It is a significant health problem in Italy, accounting 20,500 new male 
cases and 17,300 new female cases per year2.  
Regarding the mid-low locally advanced rectal cancer (LARC), studies show 
that preoperative chemoradiation (pCRT) significantly improves local control and 
reduces toxicity profiles compared to post-operative CRT with a similar survival rate3-7. 
Furthermore, the ability to achive a pathological complete response (pCR) after pCRT is 
correlated with improved survival, decresed local recurrence and higher rate of 
sphincter-preserving surgery8,9. However, although pCR rates of 20-25% can be 
obtained, more than one third of patients do not respond at all or show a poor response 
to the treatment10.  
The survival and the prognosis of patients depend on the stage of the tumour at 
the time of detection. Unfortunately more than 57% of them have regional or distant 
cancer spread at the time of diagnosis11. Despite significant advances in the 
management of CRC, the overall survival for advanced and metastatic disease has only 
little changes over the past 20 years. Five-year overall survival rate is about 64%, with 
90% 5-year survival in localized disease and 10% 5-year survival for patients with 
metastases12. Therefore, predicting the potential aggressiveness of a primary tumour 
could help in improving patient’s survival, identifying those who should receive pre- 
and post-operative CRT. Due to the not uniform response to adjuvant therapies, 
exposure to radiation or chemotherapy could be spared to patients with a priori resistant 
tumour and surgery could be scheduled without delay. Moreover, the identification of 
those patients with a complete response after pCRT could be useful to select candidates 
to a more preserving surgery (e.g. local excision of the residual scare or “wait and see” 
approach)13.  
In this scenario it is necessary to find predictive markers of response to pCRT. 
Many clinical, metabolic and radiologic tools have been evaluated as predictors of 
tumour response to pCRT, however these methods often do not correlate with 
histopatologic response. Therefore, many potential additional markers, such as 
epidermal growth factor receptor (EGFR), thymidylate synthase (TS), bcl-2/bax, 
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cyclooxygenase (COX)-2, p53, Ki-67, p21 and serum carcinoembryonic antigen (CEA) 
have been studied, but the predictive value of most of these genes is low and 
controversial14. Recent advances in expression genomics by DNA microarray have 
made possible to analyze tens of thousands of genes at a time and have shown that 
expression profile of cancer cells may be used to discriminate responders and non 
responders to pCRT15,16. On the other hand small regulatory RNAs have gained 
tremendous interest in cancer research. MicroRNAs (miRNAs) are non-coding RNA 
molecules, 18-25 nucleotides in length, which regulate the expression of their target 
genes and play an important role in the control of biological processes, such as cellular 
development, differentiation, proliferation, apoptosis and metabolism. miRNAs are 
involved in tumour biology too, including oncogenesis, progression, invasion, 
metastasis and angiogenesis. Moreover miRNAs have been recently demonstred to be 
potential markers of tumour response for rectal cancer after pCRT17,18. 
 
 
 
 
 
 
AIM 
 
The aim of this study is to investigate whether the genetic signature, gene and 
miRNA, in pretherapeutic biopsy specimens of LARC, is able to predict 
histopathological response to pCRT. 
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MATERIALS AND METHODS 
 
Patients and tissue samples 
The study encompassed consecutive patients treated in the Department of 
Surgery, Gastroenterology and Oncology of the University of Padua, Italy and in the 
Centro di Riferimento Oncologico of Aviano, Italy. All the patients were involved in 
one of the following two ongoing randomized, multicenter, phase III clinical trials: 
INTERACT and STAR. The patients fulfilled the following criteria: histological 
confirmed primary adenocarcinoma of the rectum, tumour within 12 cm from the anal 
verge by proctoscopic examination, clinical stage19 cT3-4 and/or N0-2, resectable 
disease, age ≥18 years, Karnofsky Performance Status20 ≥60%, and provision of written 
informed consent. The staging procedures, whose goal was to define the cTNM, were 
performed by digital visit, rectal/colonoscopy, transrectal ultrasound (TRUS), pelvic 
magnetic resonance imaging (MRI), and multislice computed tomography (CT). 
Baseline carcinoembryonic antigen (CEA) level was also determined. After 
pretherapeutical staging all the patients were treated with pCRT. Patient involved in the 
INTERACT trial had a total dose of 45 Gy to the whole pelvis at 1.8 Gy daily, 5 times 
per week; patients in the XELOX-RT arm got a boost of 5.4 Gy delivered to the 
mesorectum to a total dose of 50.4 Gy plus a concomitant chemotherapy with Xeloda 
and Oxaliplatin; patients in the XEL-ACRT arm got a boost of 10 Gy to the 
mesorectum, at 1 Gy for fraction to a total dose of 55 Gy plus a concomitant 
chemotherapy with Xeloda alone. The patients involved in the STAR trial were treated 
as follow: 50.4 Gy at 1.8 Gy daily, 5 times per week plus 5-Fluorouracil (5-FU) or 50.4 
Gy plus 5-FU and Oxaliplatin. The restaging was performed 4-5 weeks after the 
completion of pCRT with the same clinical/instrumental exams used for baseline 
staging.  
Surgery was planned 6-8 weeks after the completion of pCRT. The choice of 
operative procedure was at the discretion of the surgeon: low anterior resection (LAR) 
or abdominal perineal resection (APR) with standard lymphadenectomy up to the origin 
of the inferior mesenteric artery and total mesorectal excision (TME). In case of patients 
with a major clinical response (yT0-T1), documented with MRI, TRUS, and/or 
proctoscopy, a local excision was permitted, using either a conventional transanal local 
excision or the transanal endoscopic microsurgery (TEM).  
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Pathological assessment and definition of tumour response 
Standardized histological examination of the surgical specimens was done 
according to the American Joint Committee on Cancer (AJCC) guidelines19. In 
particular, the histologic tumour response to chemoradiotherapy was assessed according 
to the modified tumour regression classification of Mandart et al.21 for the oesophageal 
cancer (Figure 1). They stratified Tumour Regression Grade (TRG) in five grades: TRG 
1 (complete regression) showed absence of residual cancer and fibrosis extending 
through the different layers of the oesophageal wall; TRG 2 was characterized by the 
presence of rare residual cancer cells scattered through the fibrosis; TRG 3 was 
characterized by an increase in the number of residual cancer cells, but fibrosis still 
predominated; TRG 4 showed residual cancer outgrowing fibrosis; TRG 5 was 
characterized by absence of regressive changes. 
For the purpose of this study, patients were subdivided in responders (R, TRG 1-
2) and non responders (NR, TRG 3-5). 
 
Tissue samples and extraction of RNA 
Endoscopic tumour and normal rectal biopsies were collected from each patient 
before the beginning of pCRT, according to a standard protocol approved by the local 
ethics committee. Briefly, each patient signed an informed consent for use these 
samples for research purposes; at least 4 micro-biopsies or 1 macro-biopsy both from 
tumour and normal mucosa have been taken and immediately frozen in liquid nitrogen, 
and stored at -80°C in the Institutional BioBank. 
All biopsies underwent standardized histopathological examination by 
Haematoxylin-eosin stain on 5 µm frozen sections and tumour specimens with ≥50% 
malignant cells were considered for the experiment.  
Total RNA extraction, from at least 2 micro-biopsies, was performed using 
TRIZOL® Reagent (Invitrogen, Carlsbad, CA) following standard procedures from 
each endoscopic biopsy by sections of 20 µm thick. Total RNA was preserved in a final 
volume of 20 µl of DEPC water at -80°C with 1 µl RNase Inhibitor (RNaseOUT 
Recombinant, 40 U/µl, Invitrogen). RNA quantity was measured on an ND-1000 
spectrophotometer (NanoDrop Technologies by Celbio, Italy) and quality was assessed 
by capillary electrophoresis with Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., 
Santa Clara, CA). Samples with RIN > 6.5 (RNA 6000 Series Nano Chips) and samples 
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enriched for small nucleic acid fragments with a percentage < 35% (Agilent Small RNA 
Kit) were selected for microarray analysis. 
 
Gene expression analysis 
RNAs extracted were analyzed using microarrays technique (Agilent) with 
Whole Human Genome Oligo microarray platform 4X44K (V1); 1 µg of each sample of 
total RNA was labeled with Agilent One-Color Microarray-Based Gene Expression 
Analysis (Quick Amp Labeling, Agilent Technologies), linearly amplified, labeled and 
hybridized. Microarrays were read with the Agilent DNA Microarray scanner, and 
images were analyzed with Feature Extraction 10.5.1.1. The data were filtered and 
normalized with Moltiplicatively Detrended and Quantile methods.  
 
microRNA expression analysis 
We used Human miRNA microarray platform Rel 12.0 (V3) manufactured with 
Agilent SurePrint Technology containing 866 human and 89 human viral miRNA 
probes. The same samples used for gene expression experiments were used also for this 
analysis. 100 ng of each RNA sample were directly labeled with Agilent Cyanine3-pCp 
reagent and hybridized using the miRNA Agilent Technologies protocol. Microarrays 
were scanned and the images were analyzed. The data were filtered and normalized with 
cyclic Loess method. 
 
Statistical analysis of expression data 
The statistical analysis was performed with TMEV 4_5_1. Hierarchical 
clustering analysis was performed with complete linkage method and Euclidean 
distance. The differential gene or miRNA expressions between R and NR were found 
by SAM (Significance Analysis of Microarrays) Two Class. Class and gene prediction 
analysis was performed with PAM (Prediction Analysis for Microarray). For the 
integrative analysis of target predictions of miRNA and gene expression data a new web 
tool was used: MAGIA (miRNA and genes integrated analysis) with Pearson 
Correlation. 
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Real-time quantitative PCR 
Real-time quantitative PCR (qRT-PCR) was carried out using the SYBRTM 
Green chemistry with GeneAmp 5700 Sequence Detection System (Applied 
Biosystems) to validate ABCC2 gene expression.  
To validate miRNA expression, single-stranded cDNA from 10ng of total RNA 
samples were synthesized using MultiScribe™ MuLV reverse transcriptase (50 U/µl) 
(TaqMan® MicroRNA Reverse Transcription Kit, Applied Biosystems) and miRNA - 
specific primers (TaqMan® MicroRNA Assays). The process was carried out in three 
steps (30’ at 16°C, 30’ at 42°C, and 5’ at 85°C) and cDNA was stored at-20°C. 
The reactions of qPCR were carried out in triplicates in a final volume of 20 µl 
in 2X TaqMan Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems). 
miRNA-specific probes for 5 target miRNA (hsa-miR-630, hsa-miR-1300 v13, hsa-
miR-200a, hsa-miR-638 and hsa-miR-7) and 3 references (RNU48, RNU44 RNU6B) 
were considered for the experiments (TaqMan®MicroRNA Inventoried Assays, 
Applied Biosystems). 
qPCR was performed on an ABI 7900 HT Fast Real Time PCR instrument (10 
min. at 95°C followed by 40 cycles of 15 sec. 95°C and 1 min. 60°C). Cycle threshold 
values (Ct) were determined using the SDS software of the 7900 HT (version 2.2.2.). 
Data analysis were done using the REST software 2009 (version.2.0.13 
QIAGEN GmbH). 
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RESULTS 
 
Patient characteristics 
To identify molecular signatures of responsiveness to pCRT, we analyzed gene 
expression and miRNA expression profiles from 38 patients affected by rectal 
adenocarcinoma. Clinical data of the 38 patients are shown in Table 1. There was a 
prevalence of males (29 males vs 9 females) and the median age was 64 years. The 
median tumour distance from the anal verge was 7 cm. The majority of patients were 
clinically staged as cTNM III (n=36), while the remaining two patients were staged as 
cTNM II. The baseline CEA level was ≥ 5 ng/ml only in 6 out of 38 patients.  
The treatment characteristics are listed in Table 2. A radical tumour resection 
was achived for all patients, exept for those (n=5) who underwent local excision. For 
these 5 patients, even though radical margins have been achieved, pathological lymph 
node status remained indeterminate. The most frequent surgical procedure was LAR 
with TME (76%).  
As shown in Table 3, based on ypT stage we observed 12 (32%) good 
responders (ypT0-1), 18 (47%) non-responders (ypT3-4), and 8 (21%) intermediate 
responders (ypT2). Based on the TRG classification, there were 16 (42%) responders 
(TRG 1-2) and 22 (58%) non-responders (TRG 3-4-5). Eight patients (21%) showed a 
pathological complete response (ypT0 or TRG 1). 
 
Gene expression 
For this study, a total of 46 mRNA samples, 38 from tumour and 8 from normal 
rectal tissue biopsies, respectively, have been considered. All the 46 arrays have been 
normalized both intra- and inter-array, Figure 2 shows the data before and after 
normalization. After filtering also for background, a total of 26,330 probes have been 
considered idoneous for the analyses. 
Using TMEV 4_5_1 tool, a first unsupervised cluster analysis was done. 
Although tumour and normal samples correctly clusterized, R and NR groups did not 
clusterized, neither with complete linkage method nor with Euclidean distance. Using 
SAM Two Class, no differentially expressed genes between R and NR were found. 
Thus, the ratio between tumour sample expression and the mean of normal 
samples expression has been considered for further analyses. 
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Also in this case, a first unsupervised cluster analysis did not correctly 
clusterized R and NR groups. However, using SAM Two Class, 256 genes were found 
differentially expressed between NR and R with a FDR of 0%. As shown in Figure 3, 
188 of these genes were over- expressed and 68 down-expressed, respectively, in NR. 
Performing PAM, 12 genes were strongly predictive of tumour response, with a 
misclassification error near 0 (Figure 4). 
 
miRNA expression 
The same samples used for gene expression analysis were considered also for 
this study. In particular, the ratio between tumour sample expression and the mean of 
normal samples expression was measured. After the filtering process, a total of 159 
miRNA probes were idoneous for the analyses. 
Also in this case, a first unsupervised cluster analysis correctly clusterized 
tumour and normal samples, but did not R and NR groups. 
Using SAM Two Class, 30 miRNAs were found differentially expressed 
between NR and R with a FDR of 0%. As shown in Figure 5, 24 of these genes were 
over- expressed and 6 down-expressed, respectively, in NR. Performing PAM, we did 
not find miRNAs strongly predictive of response. 
 
Anti-correlation analysis 
For an integrative analysis of target predictions, MAGIA tool has been used with 
data obtained from the present study. Interestingly, the same 8 miRNAs are present both 
in the R and NR interaction networks, as shown in Figure 6, except for miR-630, over-
expressed only in NR group. 
 
Data validation 
For the following transcripts and miRNAs, qRT-PCR was performed: ABCC2, 
miR-7, miR182, miR-200a, miR-630, miR-638, and miR-1300, confirming the 
expression levels obtained with microarray experiments. In particular miR-7, miR182, 
and miR-200a resulted down regulated in NR group, while miR-630 and miR-1300 
were up regulated in the same group in comparison to R group. 
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DISCUSSION 
 
The response of locally advanced rectal cancers to pCRT varies tremendously. 
Although a good response to preoperative treatment is associated with favorable 
outcome, molecular markers that allow therapy stratification are still lacking22-24. The 
identification of differentially regulated genes and miRNAs could therefore contribute 
to understand better the underlying mechanisms of rectal cancer and its response to 
pCRT, in order to individualize therapy. 
This study showed that microarray technology is applicable to rectal cancer 
patients; in particular, gene and miRNA expression profiling of pre-treatment biopsies 
may be useful for predicting response to pCRT. We found 256 transcripts differentially 
expressed between responders and non responders, 12 of them were strongly predictive 
of tumour response. At the same time, 30 miRNAs resulted differentially expressed 
between responders and non responders. 
Among the differentially expressed genes, ABCC2 arises, over-expressed in non 
responders. The protein encoded by this gene is a member of the superfamily of ATP-
binding cassette (ABC) transporters. ABC proteins transport various molecules across 
extra- and intra-cellular membranes. ABC genes are divided into seven distinct 
subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a 
member of the MRP subfamily which is involved in multi-drug resistance. This protein 
is expressed in the canalicular (apical) part of the hepatocyte and functions in biliary 
transport. Anticancer drugs, such as vinblastine, are substrates of these proteins; 
therefore, this protein appears to contribute to drug resistance in mammalian cells. 
Several different mutations in this gene have been observed in patients with Dubin-
Johnson syndrome (DJS), an autosomal recessive disorder characterized by conjugated 
hyperbilirubinemia. In a recent work25, Cecchin and Coll. found that ABCC2-1249G>A 
polymorphism is associated with a better tumour response in rectal cancer patients who 
underwent pCRT. Several chemotherapeutic agents (raltitrexed, platinum derivatives, 
irinotecan, gefitinib) represent a substrate for ABCC2, supporting a possible enhanced 
exposure of patients carrying the defective polymorphism to the therapeutic effect of the 
drugs. In the present study, the over-expression of wild type ABCC2 gene was 
associated with resistance to pCRT. 
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The majority of the 12 genes strongly predictive of response (found by PAM in 
the present work) were membrane transporters; particularly interesting are BCL2L13 
and PITX2, both over-expressed in responders. BCL2L13 (or BCL-rambo) encodes a 
mitochondrially-localized protein with conserved B-cell lymphoma 2 homology motifs. 
Over-expression of the encoded protein results in apoptosis, mediated by the activation 
of Caspase-3. This is the first study in wich an over-expression of BCL2L13 is 
associated with CRC and, in particular, with a better tumour response in rectal cancer 
patients treated with pCRT.  
PITX2 gene encodes a member of the RIEG/PITX homeobox family, which is in 
the bicoid class of homeodomain proteins. The encoded protein acts as a transcription 
factor and regulates procollagen lysyl hydroxylase gene expression. This protein 
controls cell proliferation in a tissue-specific manner and is involved in morphogenesis. 
PITX2 is also a downstream effector of wnt/β-catenin signaling and seems to play a role 
in the pathogenesis of CRC. A recent work26 found that PITX2 expression is 
significantly related to the biological behavior of CRC cells and appears to be correlated 
with clinical survival. This is the first report that correlates PITX2 expression to tumour 
response in rectal cancer patients treated with pCRT. 
Among the 30 miRNAs found differentially expressed in the present study, miR-
7, miR-32, and miR-630 are particularly interesting. Bioinformatic predictions suggest 
that the human EGFR mRNA 3'-untranslated region contains three miR-7 target sites, 
which are not conserved across mammals. In Drosophila photoreceptor cells, miR-7 
controls EGFR signaling and promotes photoreceptor differentiation. Other targets of 
miR-7 are insulin-like growth factor 1 receptor (IGF1R), PIK3CD, E(spl) gene family, 
and Pak1 (cancer cells). c-Fos is also a target of miR-7b in mice. Multiple roles and 
targets of miR-7 as well as its expression pattern were linked to regulatory mechanisms 
and pathogenesis in glioblastoma, breast cancer and other types of cancers, as well as in 
schizophrenia and visual abnormalities. Inhibition of the motility, invasiveness, 
anchorage-independent growth, and tumourigenic potential of highly invasive breast 
cancer cells through the introduction of miR-7 suggests a strong therapeutic potential of 
miR-7. In a recent work27, miR-7 was identified to be significantly downregulated in 
CRC by miRNA expression array, and acts as a tumour suppressor in CRC. miR-7 
exerts its role inhibiting directly the oncogenic protein Yin Yang 1 (YY1), resulting in 
differential regulations of the functional units in p53 and wnt pathways with significant 
impact on cancer development. The same Authors revealed that YY1 was associated 
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with poor survival of CRC patients. In the present study, for the first time, an up-
regulation of miR-7 is associated with better response to pCRT for rectal cancer. 
In a recent work28, Yu and Coll. found that miR-32 over-expression was 
associated with human colon cancer stem cells (SW1116csc) and colon cancer cells 
proliferation. Moreover, Kheirelseid and Coll.29 found a miRNA predictor of complete 
response to pCRT for rectal cancer, based on a six-step model; miR-32 was one of these 
six miRNAs. Also in the present study, the over-expression of miR-32 was associated 
with a better response (TRG1-2).  
Also miR-630 has been described in CRC30. In particular, a recent work31 found 
a specific 14 miRNAs signature predictive of tumour response for rectal cancer treated 
with pCRT. miR-630 was one of these 14 miRNAs. Moreover, Galluzzi and Coll.32 
demonstrated that miR-630 was upregulated by non-small cell lung cancer A549 cells in 
response to cisplatin. In the present study, an over-expression of miR-630 was 
associated with tumour resistance to pCRT. 
Interestingly, performing anti-correlation analysis with MAGIA, the same 8 
miRNAs were found both in responder and non responder groups. Among these, miR-
638 has been yet implicated in gastric cancer, leukemia, and colorectal liver 
metastases33. miR-630 appeared only in non responders, anti-correlated with RAB5B 
gene. This is a member of RAS oncogene family, which play a central role in colorectal 
cancer tumourigenesis. It acts in protein transport, probably in vesicular traffic. This is 
the first report in which RAB5B is associated to rectal cancer response to pCRT, 
possibly under the regulation of miR-630. 
Although these results are preliminary, they are encouraging and microarray 
technology seems to be useful to find gene and miRNA expression profiling predictive 
of tumour response to pCRT in rectal cancer. However, this study has several limits. 
First, the low sample size do not permit to draw firm conclusion. Since complex 
phenotypes, such as tumour responsiveness to chemoradiotherapy, likely do not depend 
on the alteration or deregulated expression of single genes, high-throughput 
technologies have emerged as a central tool in deciphering the molecular basis of this 
clinically important phenotype because they offer the possibility to identify genomic 
differences between two groups of patients. However, due to the high number of 
observed genomic features, it represents a nontrivial task to determine which of these 
features are actually relevant, and this kind of analysis generally requires a high number 
of patients. 
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Another limitation is the few number of genes/miRNAs validated by qRT-PCR 
and the lack of validation of these results in a new prospective set of patients (ongoing 
study). Moreover, all cases of our series are from a small area of Northern Italy. 
Considering the genetic variability across different populations, it should be useful to 
perform the same analyses in a new cohort of patients possibly from another 
geographical area out of Europe. 
Several investigators have used gene or miRNA expression profiling to analyze 
the genetics of rectal cancer response to pCRT29,31,34-43. Although construction of the 
"best" predictive test in terms of clinical usefulness is desirable, the previously reported 
gene/miRNA signatures have differed considerably in terms of gene composition, with 
only few genes/miRNAs overlapping between different studies. This lack of 
concordance could be attributed to several factors, including differences in the tumour 
contents, studied populations, chemotherapy regimens, microarray platforms, 
definitions of responders, and the analytical tools used to generate the signatures. The 
current microarray predictors are not robust enough for clinical utility in rectal cancer at 
this point because of these limitations. However, considering the promising data and 
usefulness of gene profiling in breast cancer44, the microarray analysis of gene/miRNA 
expression profiling could still have the potential to improve the management of 
patients with locally advanced rectal cancer. An higher number of patients analyzed for 
confident and accurate prediction would be required in future research. Furthermore, the 
candidate genes and miRNAs included in the predictor sets should be carefully 
validated by an alternative approach, and selection of the best predictive test is required 
in terms of ensuring the clinical usefulness of such a strategy. The final hurdle is the 
requirement of the extensive validation of predictive classifiers in an independent large 
number of patients or in prospective clinical trials. 
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CONCLUSIONS 
 
Although the microarray analysis of individual tumours represents a promising 
approach to predict the responsiveness to pCRT in patients with rectal cancer, no 
optimal predictive gene expression signatures have been yet identified. Much larger 
studies using homogeneous cohorts of patients and the extensive validation of predictive 
classifiers in prospective clinical trials will be required before they can be incorporated 
into future clinical practice. 
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TABLES 
 
Table 1. Clinical characteristics (N=38) 
  N % 
Age Median (range), yrs 64 (43-79) 
Sex Male Female 
29 
9 
76 
24 
Distance from the a.v. ≤7 cm 
> 7 cm 
20 
18 
53 
47 
CEA ≤5 ng/ml 
>5 ng/ml 
32 
6 
84 
16 
cTNM 2 3 
2 
36 
95 
5 
 
a.v.: anal verge; CEA: carcinoembryonic antigen; cTNM: clinical TNM stage. 
 
 
 
Table 2. Treatment characteristics (N=38) 
 
 N % 
RT dose Median (range), Gys 50.4 (45-55) 
Concomitant ChT 
Xeloda 
Xeloda + Oxaliplatin 
5-FU 
5-FU + Oxaliplatin 
18 
13 
3 
4 
47 
34 
8 
11 
Type of surgery 
LAR 
RAR 
APR 
Local excision 
21 
8 
4 
5 
55 
21 
11 
13 
Interval pCRT-surgery  Median (range), days 50 (34-108)  
 
RT: radiotherapy; ChT: chemotherapy; 5-FU: 5-Fluorouracil; LAR: low anterior 
resection, RAR: anterior resection of rectum; APR: abdominoperineal resection; pCRT: 
preoperative chemoradiotherapy. 
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Table 3. Response to treatments (N=38) 
 
 N % 
ypT 
0 
1 
2 
3 
4 
8 
4 
8 
16 
2 
21 
11 
21 
42 
5 
TRG 
1 
2 
3 
4 
5 
8 
8 
16 
5 
1 
21 
21 
42 
13 
3 
 
ypT: pathological T stage after neoadjuvant treatments; TRG: tumour regression grade. 
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FIGURES 
 
Figure 1. Tumour Regression Grade (TRG) 
 
 
 
 
 
Figure 2. Gene expression - data normalization, a) before and b) after the process 
 
 
a) 
b) 
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Figure 3. Gene expression - SAM Two Class 
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Figure 4. Gene expression - PAM 
 
 
 
 
 
1: responders group (R) 
2: non responders group (NR) 
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Figure 5. miRNA expression - SAM Two Class 
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Figure 6. Anti-correlation analysis in a) R and b) NR groups 
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